Compare Sources
Two outlets side by side, or one story's headlines by leaning.
Novo's investigational CagriSema, a GLP-1 and amylin analog, demonstrated ~21% average weight loss with lower doses in the REDEFINE 9 trial, presented at ObesityWeek® 2026 and published in The Lancet Diabetes & Endocrinology
No rated outlets yet
Left 0 articles
No outlets from this side.
Centre 0 articles
No outlets from this side.
Right 0 articles
No outlets from this side.
How this was worked out
Headlines grouped by the leaning of their outlet. “Words this side uses more” are headline words at least 2.5 times more common on that side than on the other two, used by at least 2 of its outlets.
How INDB scores stories · Data: stories INDB grouped from the outlets on the sources page.